Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
canceR agnOstic immUnoTherapy predIctioN blood-tEst (ROUTINE)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Challenges
Action type: EIC actions
Countries involved: Netherlands
Call: EIC Accelerator Challenge: Novel biomarker-based assays to guide personalised cancer treatment (HORIZON-EIC-2023-ACCELERATOR-01, 2023)
Start date: 2023-08-01
End date: 2025-07-31
Duration (months): 24.0
Total project cost (EUR): 3669631.25
EU funding (EUR): 2500000.0
Participants: 1
Project status: CLOSED

Cancer is the second leading cause of death worldwide, accounting for 10M deaths in 2020. Although 7 Immune Checkpoint Inhibitors (ICI) are approved for different cancer indications and have represented a true breakthrough, only 10-50% of advanced cancer patients respond to the treatment. This unpredictability of results, together with 15-60% severe toxicity rates and high prices are restricting the impact potential of ICIs. Predicting ICI response is critical for fully realizing their potential in treating early-stage tumours and enhancing ICI treatment regimens. PamGene’s IOpener is a ground-breaking in vitro diagnostics testing platform for ICI response prediction. Made possible by PamGene’s proprietary microarray-based kinase activity profiling of host immune cells, it can predict a patient’s response before ICI therapy is started from a simple blood draw. The IOpener aims to revolutionize the precision-medicine sector, enabling the widespread use of ICIs at any cancer stage.

Keywords: in vitro diagnostic testing platform,immunotherapy response prediction tool,kinase activity profiling,multi omics,immune checkpoint inhibitors
Beating organs on chip Revolutionize Advanced therapies' discovery Valuing Effective preclinical models (BRAVE)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Italy
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 10000000.0
EU funding (EUR): 10000000.0
Participants: 1
Project status: SIGNED

BIOMIMX is an R&D-performing SME, pioneering the Organ-on-Chip (OoC) field. BiomimX proposes a new generation of in vitro preclinical tools, built upon a proprietary cutting-edge technological platform (Beating Organs on Chip), which enables to generate in vitro replica of human tissues with an unprecedented level of clinical resemblance. This provides a window into human organs and complex diseases, without involving animals. The result is a more reliable, responsive, and predictive in vitro model to investigate new therapies, solving a main pain of drug developmental process (DDP) stakeholders. Pharma research and development (R&D) is indeed an area where animal models continue to fall short due to lack of translatability and/or lack of relevant models. Regulatory agencies in the US and Europe are now moving forward to encourage biopharma’s use of more predictive non-animal alternatives. BIOMIMX is poised to be a leader in this space and has gained early traction with industry. Within the BRAVE project, BIOMIMX aims at demonstrating the unprecedented potential of Beating Organs on Chip disruptive innovation in reshaping the market of drug development, by i) boosting technological aspects and ii) proving the versatility of its innovation and its capacity to adapt to a manifold of indications and market spaces. BIOMIMX main objective is to partner with Pharma and Biotech companies through long-term agreements in the framework of their drug discovery programs. BiomimX already engaged customers among top-10 Pharma through pilot studies, where tailor-made models are setup to show the potentiality of BiomimX solutions. To ensure a successful path towards the accomplishment of its vision, BiomimX Team combines >10 years of experience in microtechnology, advanced 3D in vitro culture, business development through our core team (all PhD level).

Keywords: preclinical models organs on chip alternative to animal models
The Effect of Alpha emitters and Radiofrequency Fields on cancer cells in culture. (TEARF)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Attracting and mobilising the best talents
Destination: Attracting and mobilising the best talents
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Lithuania,Norway
Call: ERA Fellowships (HORIZON-WIDERA-2024-TALENTS-02, 2024)
Start date: 2026-03-01
End date: 2028-02-29
Duration (months): 24.0
Total project cost (EUR): 196976.16
EU funding (EUR): 196976.16
Participants: 2
Project status: SIGNED

The Effect of Alpha emitters and Radiofrequency Fields on cancer cells in culture. Alpha emitter radiation therapy involves the use of radionuclides that decay, emitting an alpha particle that kills the cancer cells. Radiopharmaceuticals that emit low levels of alpha particle radiation are used to treat different cancers. Compared to other treatment options such as external beam radiation and chemotherapy, alpha emitter radiation therapy results in better treatment outcome. There are however side effects such as pancytopenia, which may be attributed to the radiation dose administered to the patient. Combination therapy may lead to the use of lower doses of alpha emitters, achieving the desired treatment outcome with reduced side effects. An effective treatment regimen is one that kills the cancer cells with minimal to no normal tissue toxicity. There is, therefore, a need to explore other methods as modulators or modifying agents of the alpha emitter radiation therapy. Radiofrequency fields (RF) have been evaluated for their role as modulators of external beam radiation hence, they are good candidate to assess as modulators of alpha emitter radiation therapy. In the proposed work RF will be evaluated as potential modifying agents for alpha emitter radiation therapy using Ra-223. This project seeks to explore multimodality therapeutic approaches, for better treatment outcomes.

Keywords: radionuclide therapy,radiofrequency fields,
A novel Laser-Induced Forward Transfer (LIFT) printer to deposit solder paste and disrupt Surface Mount Technology microelectronics industry (LIFT printer)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Netherlands
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 3600000.0
EU funding (EUR): 3600000.0
Participants: 1
Project status: SIGNED

The Surface Mount Technology (SMT) industry faces significant challenges due to the increasing complexity of PCB assembly, driven by the miniaturization of components and a shortage of qualified personnel. The manual and experience-based nature of stencil printing lacks the flexibility and digitalization needed to handle this evolving technological landscape efficiently. Current assembly methods are not reliable and are sensitive to failures, necessitating multiple inspection systems and manual corrections before production can commence. This reliance on screen and jet printers, along with Solder Paste Inspection (SPI) equipment, increases operational costs and leads to frequent downtimes, yield losses, and environmental concerns. Keiron’s solder paste printer, leveraging Laser Induced Forward Transfer (LIFT) technology, offers a promising solution to these challenges. By replacing traditional stencil and jet printers and SPI equipment, Keiron’s printer delivers better yields and improved production line utilization. The LIFT process uses a laser to transfer functional materials from a transparent carrier onto the product, eliminating the need for stencils and nozzles. Keiron’s printer features a compact design, is backed by licensed patents, and offers superior performance and efficiency for high-resolution printing. In the EIC project, Keiron aims to enhance the robustness and reliability of LIFT through rigorous testing and optimization, ensuring consistent performance in varied manufacturing conditions. Subsequently, Keiron will then Implement efficient production preparation protocols and conduct comprehensive testing in real-world environments to validate performance. Following this, Keiron will optimize and industrialize the design to prepare for scaling up to high-volume production. The company will expand its team and leverage strategic partnerships in the SMT and electronics manufacturing sectors to facilitate market entry.

Keywords: surface mount technology,industry 4 0,solder paste printing
HARNESSING HARDWARE, SOFTWARE, AND AI PLATFORM TO CONVERT OLD FASHIONED AUSCULTATION INTO DIGITAL BIOMARKERS (AISOUND)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Netherlands
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Through a Revolutionary Sound Platform based on an ever evolving (firmware that updates through the internet) hardware, software (SOUNDS OS), and AI, Lapsi presents multiple products focused on sound acquisition, analysis and monitoring of pathologies. Starting from a first product, known as Keikku, Lapsi intends to update the already developed platform (2.0) through improvements and new implementations of firmware and AI algorithms; thus, obtaining a second iteration with an enhanced architecture, known as iLo. Once this is achieved, Lapsi will develop numerous products (Air) while maintaining both the hardware and the platform and will only upgrade the firmware.

Keywords: convert old fashioned auscultation into digital biomarkers
Development and industrial validation of BioRenGaz’s anaerobic bioreactor which optimises the dark fermentation of biological hydrogen production from food biowaste. (BioRenGaz)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Food waste presents a pressing challenge with far-reaching implications on a global scale and throughout the European Union (EU). The EU, grappling with an annual 88 million tonnes of food waste costing €143 billion and causing 170 million tonnes of CO2 emissions, requires an innovative approach. Globally, one-third of food production is lost or wasted, contributing to 8-10% of greenhouse gas emissions. Farmers, local authorities, and the food industry struggle with non-valorised waste streams, hindering circular economy promotion. This is caused by several technical and logistic challenges that prevent stakeholders from adopting fermentation technology to valorise such waste. Traditional anaerobic digestion methods suffer from inefficiencies, causing suboptimal biowaste recovery and impacting economic feasibility. Moreover, centralized hydrogen production and transportation pose hazards, high operational costs, and energy loss, emphasizing the urgent need for innovative waste recovery solutions. BioRenGaz introduces an advanced solution to the global challenge of biowaste mismanagement. Our innovative technology specializes in anaerobic digestion, efficiently transforming food waste into valuable biogas on-site. Our groundbreaking thermophilic fixed culture digester, equipped with patented culture media derived from recycling and 100% renewable sources, optimizes bacterial performance while addressing environmental concerns. Our value proposition lies in achieving four times greater efficiency, a 10-fold reduction in surface area, and a 10% boost in gas production, a 75% reduction in operational costs, promotion of sustainable agriculture, and substantial reductions in greenhouse gas emissions. In this EIC project, BioRenGaz will enhance its bioreactor and process efficiency and conditions by rigorous testing and refinement for optimal biohydrogen production and economic viability to ultimately validate at a large industrial scale.

Keywords: anaerobic digestion,waste valorization renewable energy biogas production eco friendly agriculture circular economy food waste management decentralized hydrogen production sustainable technology
Project GEN+: Generative AI for Digital Biomarkers (ColboltGen)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Ireland
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2499999.0
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

Central Nervous System conditions and Rare Disease impact over 1 billion people worldwide. 90% of patients experience symptoms despite medication and many of these conditions have no drug therapy at all. 82% of these patients experience issues accessing care for their symptoms, resulting in a cost burden of over €300bn annually in Europe. On top of this, there is a lack of breakthrough therapies as 85% of CNS drug trials fail, at a cost of €1bn per failure. Through Project ColboltGEN+, Beats Medical can accelerate our proprietary digital biomarkers approach through Generative AI to make pharma trials more efficient and more successful, unlocking the breakthrough therapies of the future. Building on our core technology which provides digitized versions of gold standard assessments of gross motor, fine motor and speech symptoms, Beats Medical can validate existing and discover new digital biomarkers (precision indicators of disease presence or progression) which will allow for better patient subgrouping, tracking of treatment response and will lead to faster breakthroughs. Through the project we will advance two innovations from TRL 5 and TRL 6 to TRL 8. Beats Medical have a proven ability to deliver, having successfully completed a Horizon 2020 grant project with all milestones and deliverables met including a 25% revenue increase. We have validated our market for this innovation with 7 of the top 20 global pharma active in our sales pipeline. We have proven our ability to partner with Pharma, having closed a licence agreement with top-10 global pharma Sanofi. Beats Medical has generated over €1m in revenue to date from our existing technology POC’s, and through Project ColboltGen+ we can expand our market ten-fold, increasing our staff by over 100 by 2029, closing 5 Pharma partnerships to generate over €100M in revenue which will make Beats Medical the European-owned market leader in the industry that will be the next frontier of medicine, digital biomarkers.

Keywords: generative ai digital biomarkers cns neurology medicine assessments therapies pharmaceutical breakthrough large language model drug discovery
A Risk Assessment platform for all things AI (CitrusX)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

In a world where AI is rapidly transforming industries, CitrusX empowers you to harness its true potential. Don't allow the intricacies, accuracy challenges, or liability risks deter you from adopting AI. Join the AI revolution today, embrace CitrusX, and revolutionize your AI/ML behavior analysis, opening doors to innovation and unparalleled insights. Our solution is urgently needed, as 87% of ML models never make it to production. Tech giants like Google, Microsoft, and Facebook have unsuccessfully tried to improve their AI’s ethical issues and have highlighted the following fundamental principles as vital for improving AI’s ethical training: fairness, inclusiveness, reliability and safety, transparency, privacy and security, and accountability. CitrusX is revolutionizing AI/ML behavior analysis. CitrusX offers a state-of-the-art AI/ML risk assessment platform that leverages proprietary technology to precisely analyze and assess risks in AI/ML models before they go into production and to safeguard them once deployed. CitrusX provides a comprehensive solution for developing and deploying AI models, structured to enhance transparency, accuracy, and regulatory compliance throughout the model lifecycle, including the development phase, vulnerability assessment, model comparison, model onboarding, operational monitoring, management dashboard, and executive reporting. We founded CitrusX Ltd. in late 2021 and target the €45.5B financials and insurance market with a yearly subscription pricing per model per year. CirusX was co-founded by CEO Noa Srebrnik and CTO Gilad Manor, who lead our team of 15 people. CitrusX will have a game-changing impact on the adoption of AI in the EU as our technology can help comply with the AI Act.

Keywords: ai lifecycle,ml model performance,ai adoption,ai compliance,black box,ai investment,ai model behavior,ai fairness,ai driven applications,ai transparency,complex systems,ai initiatives
Operando Interfacial Ionics (ORION)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Physical and Analytical Chemical Sciences
Panel description: Analytical chemistry, chemical theory, physical chemistry/chemical physics
Countries involved: Germany
Call: ERC STARTING GRANTS (ERC-2022-STG, 2022)
Start date: 2023-01-01
End date: 2027-12-31
Duration (months): 60.0
Total project cost (EUR): 1749203.75
EU funding (EUR): 1749203.75
Participants: 1
Project status: SIGNED

Electrochemistry provides direct control over the electron free energy and thus a path to electrically probe and drive chemical reactions. In strong contrast, no versatile technique exists that controls the free energy of a specific ion directly and in isolation. This has led to poor understanding of interfacial ionics. Take for example water dissociation , which is of key relevance for many energy technologies, such as for producing green H2 in alkaline conditions or bipolar membranes (BPMs) that generate acid and base using (renewable) electricity in electrodialysis. BPMs are unique, because they isolate water dissociation spatially at a junction between two electrically-isolating, but ionically-conducting polymers. However, macroscopic BPMs do not provide x-y-z resolution. These geometric constraints limit our scientific understanding about the fundamental underpinnings of WD. It is not still clearly understood what causes the kinetic barriers of WD at heterogeneous interfaces, let alone the influence of the catalyst’s surface structures or local electrostatics. In Orion, I want to scale down the ion-selective contacts of the BPM and develop “ionomer pipette microscopy”. By forming and controlling a microscopic BPM junction, we will resolve and study WD activity as a function of crystal facets, metal oxide clusters and bias-dependent surface speciation. In general, water dissociation serves us as ionic test reaction to study the impact and link between local electrostatics and local acid-base chemistry, which is fundamentally important for interfacial ionics in general. More broadly, developing a table-top setup to control the free energy of specific ions with microscopic precision could have tremendous impact across the disciplines. Example include interfacial ion transport in solid-state electrochemical systems, (de)hydrogenation in organic chemistry and enzyme function, proton gradients and action potentials in biochemistry.

Keywords: water dissociation,ionic interface processes,bipolar membrane,scanning ion conductance microscopy,electrocatalysis
Smart Fenton OXidation: a catalytic membrane for water purification (S-FOX)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: France
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-12-01
End date: 2024-11-30
Duration (months): 24.0
Total project cost (EUR): 195914.88
EU funding (EUR): 195914.88
Participants: 1
Project status: CLOSED

The main goal of this project is the development of new polymeric catalysts and new catalytic membranes, designed to carry out high-end chemical oxidation in aqueous streams. Catalytic membranes are means to perform chemical transformation at the solid/ fluid interface and they are ideal interfacial reactors and contactors, simultaneously catalyzing and directing the heterogeneous phase reaction between substrates and oxidant agents. These systems have a key role in the future process industry and in water treatment since they enable oxidation reactions whilst reducing reagents and waste. Current systems employ inorganic and often high-value catalysts, which are generally of high cost, and prone to leaching causing loss of performance in time. I propose the first fully polymeric catalytic membrane made exclusively of bio-inspired iron coordination polymers. This research will lead to key scientific breakthroughs by: i) creating new non-heme catalytic polymers that mimic the activity of biological enzymes and that can be efficiently deployed to cast membranes for heterogeneous reaction; ii) designing and fabricating polymeric membranes consisting of the catalytic macromolecules and with suitable surface and morphological properties to precisely guide and enhance the contact among the reagents and with the catalyst; iii) successfully applying these systems maintaining high catalytic rate and yield and to understand the mechanisms and pathways of transformation of compounds, especially water micropollutants. These innovations will enable membrane robustness, long-term efficiency, and low cost. In particular, the potential of the new catalysts, membranes, and membrane reactors will be exemplified in the purification of contaminated streams to produce safe water. Thus, this new system represents a platform for a plethora of further advances in the field of oxidation processes applied to chemistry, engineering, and the environment.

Keywords: catalytic membrane,advanced oxidation process,contaminants of emerging concern,polymeric non heme catalysts